Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

Table 1

Demographic, clinical, and radiological characteristics in 20 relapsing remitting multiple sclerosis (RRMS) patients receiving Natalizumab.

Sex: female/male	17/3
Age at entry, years: mean ± SD	34.2 ± 9.8
Disease duration at baseline, years (mean ± SD)	10.2 ± 6.2
Disease severity at baseline, EDSS: mean ± SD	1.3 ± 1.5
EDSS after 21 months of treatment (mean ± SD)	1.7 ± 1.7
Relapsing/nonrelapsing patients during 21 months of therapy	5/15
Patients with/without new MRI lesions at the end of treatment	4/20

EDSS = Expanded Disability Status Scale; MRI = Magnetic Resonance Imaging; SD = standard deviation.